Are statins anti-inflammatory?

Large scale clinical trials demonstrate significant reductions in cardiovascular event rates with statin therapy. The observed benefit of statin therapy, however, may be larger in these trials than that expected on the basis of lipid lowering alone. Emerging evidence from both clinical trials and basic science studies suggest that statins have anti-inflammatory properties, which may additionally lead to clinical efficacy. Measurement of markers of inflammation such as high sensitivity C-reactive protein in addition to lipid parameters may help identify those patients who will benefit most from statin therapy.

• Publication year

  2000

• Venue

  Current Controlled Trials in Cardiovascular Medicine

• Publication date

  2000-11-30

• Fields of study

  Medicine

• Identifiers
  DOI 10.1186/cvm-1-3-161PMID 11714433PMCID 59622
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The New England Journal

  2000cited by this paper
• Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses

  2000cited by this paper
• Simvastatin inhibits the monocyte expression of proinflammatory cytokines in patients with hypercholesterolemia.

  2000cited by this paper
• Are statins anti-inflammatory? Issues in the design and conduct of the pravastatin inflammation C-reactive protein evaluation

  2000cited by this paper
• Elevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarction.

  2000cited by this paper
• Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men.

  2000cited by this paper
• C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women.

  2000cited by this paper
• Fluvastatin Inhibits Matrix Metalloproteinase-1 Expression in Human Vascular Endothelial Cells

  2000cited by this paper
• Atherosclerosis--an inflammatory disease.

  1999cited by this paper
• Pravastatin therapy in hyperlipidemia: effects on thrombus formation and the systemic hemostatic profile.

  1999cited by this paper
• Long-Term Effects of Pravastatin on Plasma Concentration of C-reactive Protein

  1999cited by this paper
• Statins and C-reactive protein.

  1999cited by this paper
• Inhibition of thrombin generation by simvastatin and lack of additive effects of aspirin in patients with marked hypercholesterolemia.

  1999cited by this paper
• Protective effect of fluvastatin sodium (XU-62-320), a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, on oxidative modification of human low-density lipoprotein in vitro.

  1999cited by this paper
• Effect of statins on C-reactive protein in patients with coronary artery disease.

  1999cited by this paper
• Statins and C-reactive protein.

  1999cited by this paper
• Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators.

  1999cited by this paper
• Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly.

  1999cited by this paper
• Statins and monocytes.

  1999cited by this paper
• Inhibition of proinflammatory cytokine production by pravastatin.

  1999cited by this paper
• Atorvastatin and gemfibrozil metabolites, but not the parent drugs, are potent antioxidants against lipoprotein oxidation.

  1998cited by this paper
• Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators.

  1998cited by this paper
• Plasma concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men.

  1998cited by this paper
• Current and future treatment of hyperlipidemia: the role of statins.

  1998cited by this paper
• Pravastatin has cholesterol-lowering independent effects on the artery wall of atherosclerotic monkeys.

  1998cited by this paper
• 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors increase fibrinolytic activity in rat aortic endothelial cells. Role of geranylgeranylation and Rho proteins.

  1998cited by this paper
• C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction.

  1998cited by this paper
• Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase.

  1998cited by this paper
• Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors.

  1998cited by this paper
• B-mode ultrasound assessment of pravastatin treatment effect on carotid and femoral artery walls and its correlations with coronary arteriographic findings: a report of the Regression Growth Evaluation Statin Study (REGRESS).

  1998cited by this paper
• Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study.

  1998cited by this paper
• HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages.

  1998cited by this paper
• HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis.

  1998cited by this paper
• Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels.

  1998cited by this paper
• Interactions of platelets, macrophages, and lipoproteins in hypercholesterolemia: antiatherogenic effects of HMG-CoA reductase inhibitor therapy.

  1998cited by this paper
• Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: the Atherosclerosis Risk In Communities (ARIC) study.

  1997cited by this paper
• Vastatins inhibit tissue factor in cultured human macrophages. A novel mechanism of protection against atherothrombosis.

  1997cited by this paper
• Effects of fluvastatin on leukocyte-endothelial cell adhesion in hypercholesterolemic rats.

  1997cited by this paper
• Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month.

  1997cited by this paper
• Proapoptotic effect of atorvastatin on stimulated rabbit smooth muscle cells.

  1997cited by this paper
• HMG-CoA reductase inhibitors decrease CD11b expression and CD11b-dependent adhesion of monocytes to endothelium and reduce increased adhesiveness of monocytes isolated from patients with hypercholesterolemia.

  1997cited by this paper
• West of Scotland Coronary Prevention Study: identification of high-risk groups and comparison with other cardiovascular intervention trials.

  1996cited by this paper
• Contrary effects of lightly and strongly oxidized LDL with potent promotion of growth versus apoptosis on arterial smooth muscle cells, macrophages, and fibroblasts.

  1996cited by this paper
• Inhibitory effect of fluvastatin, an HMG-CoA reductase inhibitor, on the expression of adhesion molecules on human monocyte cell line.

  1996cited by this paper
• The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators.

  1996cited by this paper
• Non-lipid-related effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors.

  1996cited by this paper
• Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group.

  1995cited by this paper
• The Scandinavian Simvastatin Survival Study (4S)

  1995cited by this paper
• Effect of pravastatin on outcomes after cardiac transplantation.

  1995cited by this paper
• Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia

  1995cited by this paper
• Cholesterol, diastolic blood pressure, and stroke: 13,000 strokes in 450,000 people in 45 prospective cohorts. Prospective studies collaboration.

  1995cited by this paper
• Disease-free intervals after partial ileal bypass in patients with coronary heart disease and hypercholesterolemia: report from the Program on the Surgical Control of the Hyperlipidemias (POSCH).

  1995cited by this paper
• Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

  1994cited by this paper
• Simvastatin inhibits the oxidation of low-density lipoproteins by activated human monocyte-derived macrophages.

  1993cited by this paper
• The role of tissue factor pathway inhibitor in a revised coagulation cascade.

  1992cited by this paper
• Hypolipidemic drugs reduce lipoprotein susceptibility to undergo lipid peroxidation: in vitro and ex vivo studies.

  1992cited by this paper
• The cellular functions of small GTP-binding proteins.

  1990cited by this paper
• The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease.

  1984cited by this paper

• Circulating inflammation-related proteome improves cardiovascular risk prediction. Results from two large European cohort studies

  2025cites this paper
• The Role of Neuroinflammation in the Comorbidity of Psychiatric Disorders and Internal Diseases

  2025cites this paper
• Formulation and Evaluation of Simvastatin Loaded Nanostructured Lipid Carrier for Topical Drug Delivery

  2025cites this paper
• Assessment of Efficacy and Safety of Lipid-Lowering Treatment and Its Importance in Risk Assessment and Prevention in a Hungarian Myositis Cohort

  2025cites this paper
• Atorvastatin Confers Renoprotection and Modulates Inflammation in Diabetic Rats on a High-Fat Diet

  2025cites this paper
• The Role of Statins in Managing Chronic Kidney Disease: A Comprehensive Review

  2025cites this paper
• In silico biological discovery with large perturbation models

  2025cites this paper
• The Potential Benefits of a Novel Food Supplement Based on Cannabis Sativa, Boswellia, and Fish Oil for Pain and Inflammation in Physical Activity: Unraveling the Role of Orexin-A Modulation

  2025cites this paper
• Knowledge, attitudes and practices in HIV-related chronic inflammation and cardiovascular risk in Spain.

  2023cites this paper
• The pathogenic role of foam cells in atherogenesis: Do they represent novel therapeutic targets?

  2022cites this paper
• Update on Statin Treatment in Patients with Neuropsychiatric Disorders

  2021cites this paper
• Idiopathic chronic pancreatitis: Beyond antioxidants

  2021cites this paper
• Effectiveness Of 1.2% Simvastatin Gel as an Adjunct to Non-Surgical Therapy in The Treatment of Chronic Periodontitis: A Split Mouth Randomized Controlled Trial

  2021cites this paper
• Statin use in patients with non‐HMGCR idiopathic inflammatory myopathies: A retrospective study

  2020influential citation
• Statin use is associated with reduced mortality after respiratory viral infection

  2020cites this paper
• Selected pharmacotherapy agents as antiproliferative and anti‐inflammatory compounds

  2020influential citation
• Antifungal efficacy of atorvastatin-containing emulgel in the treatment of oral and vulvovaginal candidiasis.

  2020cites this paper
• Preinjury Statins Are Associated With Improved Survival in Patients With Traumatic Brain Injury.

  2019cites this paper
• Effects of Atorvastatin Alongside Conventional Medical Treatment on Liver Fibrosis and Dysfunction in Patients with Chronic Hepatitis B: A Double-Blinded Clinical Trial

  2019cites this paper
• Computational Tools for the Untargeted Assignment of FT-MS Metabolomics Datasets

  2019cites this paper
• Foam cell formation: A new target for fighting atherosclerosis and cardiovascular disease.

  2019cites this paper
• Markers of Oxidative Stress and Inflammation in only Diabetic and Obese Ghanaian Populations: The RODAM Study

  2019cites this paper
• Preoperative leukocyte count and postoperative inpatient mortality in South African non-cardiac surgery patients

  2019cites this paper
• The risk of cancer in statin users : a clinical and genetic approach

  2019cites this paper
• Cell & Molecular Biology of Prostate Cancer

  2018cites this paper
• A Cure of Coronary Artery Disease by Removing Atheromatous Plaques from Coronary Arteries in a Diabetic Patient

  2018cites this paper
• Atorvastatin treatment softens human red blood cells: an optical tweezers study.

  2018cites this paper
• Transcriptional profiling identifies novel regulators of macrophage polarization

  2018cites this paper
• Inflammation and Prostate Cancer.

  2018cites this paper
• Chronic Use of Statins and Their Effect on Prevention of Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis

  2018cites this paper
• Atorvastatin treatment softens human red blood cells: an optical tweezers study

  2018cites this paper
• Targeting HMGB1/TLR4 axis and miR-21 by rosuvastatin: role in alleviating cholestatic liver injury in a rat model of bile duct ligation

  2018cites this paper
• Statins Suppress Ebola Virus Infectivity by Interfering with Glycoprotein Processing

  2018cites this paper
• Novel pro- and anti-atherogenic effects of apolipoprotein B-containing lipoproteins: To feast or to fast?

  2017cites this paper
• Pro-Atherogenic Oxidized Ldl/β2-Glycoprotein I Complexes in Diabetes Mellitus: Antioxidant Effect

  2017cites this paper
• Simvastatin reduces vaso‐occlusive pain in sickle cell anaemia: a pilot efficacy trial

  2017cites this paper
• A Cure for Coronary Artery Disease

  2017cites this paper
• In vivo evidence for chylomicrons as mediators of postprandial inflammation.

  2015cites this paper
• The effect of cardioprotective diet rich with natural antioxidants on chronic inflammation and oxidized LDL during cardiac rehabilitation in patients after acute myocardial infarction

  2015cites this paper
• ANTI-INFLAMMATORY ACTIVITY OF HMG CO A REDUCTASE INHIBITORS: A COMPARATIVE STUDY Short Communication

  2015cites this paper
• Comparative evaluation of HMG CoA reductase inhibitors in experimentally-induced myocardial necrosis: Biochemical, morphological and histological studies.

  2015cites this paper
• Biomarcadores preditivos de mortalidade em doentes renais crónicos em hemodiálise. Perfil lipídico, anemia, acesso vascular e inflamação.

  2015cites this paper
• STATIN THERAPY IN PATIENTS WITH ANKYLOSING SPONDYLITIS

  2015cites this paper
• Efficacy of subgingivally delivered atorvastatin and simvastatin as an adjunct to scaling and root planing

  2015cites this paper
• Low Serum High Density Lipoprotein Cholesterol Concentration is an Independent Predictor for Enhanced Inflammation and Endothelial Activation

  2015cites this paper
• Statin therapy and plasma vitamin E concentrations: A systematic review and meta-analysis of randomized placebo-controlled trials.

  2015cites this paper
• ANTI-INFLAMMATORY ACTIVITY OF HMG CO A REDUCTASE INHIBITORS: A COMPARATIVE STUDY

  2015cites this paper
• Neuroprotective Effect of Rosuvastatin on Ca1 & Ca3 Regions of Hippocampus in High Fat Diet and Stress Induced Rats

  2014cites this paper
• The Effect of Short-Term Cardiac Rehabilitation After Acute Myocardial Infarction on High-Sensitivity C-Reactive Protein

  2014cites this paper
• Modulation of obesity-induced inflammation by dietary fats: mechanisms and clinical evidence

  2014cites this paper
• Anticorpos contra Lipoproteína de baixa densidade oxidada (oxLDL) e peptídeo da apolipoproteína B apoB (apoBD) como possível marcador no acompanhamento da eficácia do tratamento com Rosuvastatina em pacientes hipercolesterolêmicos

  2013cites this paper
• Pro-Inflammatory Genetic Markers of Atherosclerosis

  2013cites this paper
• Pharmacoepidemiologic studies: An interrupted-time series analysis on drug utilization and evaluation of beneficial or adverse drug effects

  2013cites this paper
• Colchicine and the heart: pushing the envelope.

  2013cites this paper
• Anticorpos contra Lipoproteína de baixa densidade oxidada (oxLDL) e peptídeo da apolipoproteína B apoB (apoBD) como possível marcador no acompanhamento da eficácia do tratamento com Rosuvastatina em pacientes hipercolesterolêmicos

  2013cites this paper
• Reduced arterial compliance in patients with psychiatric diagnoses.

  2012cites this paper
• The evaluation of analgesic effects of simvastatin, pravastatin and atorvastatin in hot plate test.

  2012cites this paper
• Effect of hydroalcoholic extract of Hypericum perforatum on selected traditional and novel biochemical factors of cardiovascular diseases and atherosclerotic lesions in hypercholesterolemic rabbits: A comparison between the extract and lovastatin

  2012cites this paper
• Synovial xanthomatosis: are there clues to mechanisms for this rare disease?

  2012cites this paper
• Older people and functional foods: a role to play, but no silver bullet

  2011cites this paper
• A pilot study of the short‐term use of simvastatin in sickle cell disease: effects on markers of vascular dysfunction

  2011cites this paper
• Effects of immunomodulatory drugs on plasma inflammatory markers in a rabbit model of atherosclerosis

  2011cites this paper
• Biology of redox active endosomal signaling in response to Il-1-Beta

  2011cites this paper
• Hyper-IgD syndrome and hereditary periodic fever syndromes

  2011cites this paper
• What are functional foods and what they can do

  2011cites this paper
• Rosuvastatin treatment is associated with a decrease of serum oxidised low-density lipoprotein/beta2-glycoprotein I complex concentration in type 2 diabetes

  2010cites this paper
• Effects of statins on the secretion of human serum albumin in cultured HepG2 cells

  2009cites this paper
• Validated treatments and therapeutics prospectives regarding pharmacological products for sarcopenia

  2009cites this paper
• Cytokine-Induced Sickness Behavior and Depression

  2009cites this paper
• Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases

  2008cites this paper
• Impact of traditional therapies and biologics on cardiovascular diseases in rheumatoid arthritis.

  2008influential citation
• Potential utility of changes in entropy as an adjunct to the electrocardiography diagnosis of reversible myocardial ischaemia.

  2008cites this paper
• Therapeutic potential of statins in multiple sclerosis: immune modulation, neuroprotection and neurorepair.

  2008cites this paper
• Hypolipidemic and antihypertensive drugs for prevention of cardiovascular complications in patients with rheumatoid arthritis

  2008cites this paper
• Influenza and COPD mortality protection as pleiotropic, dose-dependent effects of statins.

  2007cites this paper
• CD40/CD40L system and vascular disease

  2007cites this paper
• Immunomodulatory effects of statins and autoimmune rheumatic diseases: novel intracellular mechanism involved.

  2006cites this paper
• Rôle du récepteur nucléaire RORαdans la survie et la différenciation neuronale

  2006cites this paper
• Retroperitoneal Fibrosis, Today: An Updating of Knowledges on this Subjet

  2006cites this paper
• Inflammation: a pivotal link between autoimmune diseases and atherosclerosis.

  2006cites this paper
• Overexpression of lysosomal acid lipase and other proteins in atherosclerosis.

  2006cites this paper
• Rheumatoid arthritis and cardiovascular disease: the role of systemic inflammation and evolving strategies of prevention

  2005cites this paper
• Osteoporosis and atherosclerosis: biological linkages and the emergence of dual-purpose therapies.

  2005cites this paper
• Predictive Value of Soluble Intercellular Adhesion Molecule-1 for Risk of Ischemic Events in Individuals with Cerebrovascular Disease

  2005cites this paper
• Können Statine den Knochenstoffwechsel positiv beeinflussen

  2005cites this paper
• Bezafibrato más Ezetimiba en el tratamiento de dislipidemia mixta

  2005cites this paper
• Can Statins Be Considered as a Tertiary Level Agent in Patients with Failure of Conventional Oral Hypoglycemic Agents?

  2005cites this paper
• CD40 Ligand: A Novel Target in the Fight against Cardiovascular Disease

  2004cites this paper
• The “CholesteROR” Protective Pathway in the Vascular System

  2004cites this paper
• Simvastatin inhibits lymphocyte function in normal subjects and patients with cardiovascular disease.

  2004cites this paper
• Statins but not fibrates are associated with a reduced risk of venous thromboembolism: a hospital‐based case–control study

  2004cites this paper
• The antithrombotic profile of aspirin. Aspirin resistance, or simply failure?

  2004cites this paper
• Increases in Serum Non‐High‐Density Lipoprotein Cholesterol May Be Beneficial in Some High‐Functioning Older Adults: MacArthur Studies of Successful Aging

  2004cites this paper
• Pleiotropic Effects of Statins

  2004cites this paper
• Do statins offer therapeutic potential in inflammatory arthritis?

  2004cites this paper
• Pharmacoepidemiology and disability in older adults: can medications slow the age-related decline in physical function?

  2004cites this paper
• Therapeutic strategies for rheumatoid arthritis.

  2004cites this paper
• Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial.

  2004cites this paper
• Les marqueurs inflammatoires chez les dialysés : données épidémiologiques

  2003cites this paper
• C-Reactive Protein for Primary Risk Assessment

  2003cites this paper